SCHEMBL755867

SCHEMBL755867

C1COC2(CCC3(CC3)CC2)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2236435 0.89
SCHEMBL1809810 0.89 L3MBTL1 (0.32)
SCHEMBL15605637 0.87
SCHEMBL3511528 0.82
SCHEMBL31715737 0.80 GAA (0.33)
SCHEMBL17256630 0.78
SCHEMBL5665559 0.76
SCHEMBL30942897 0.76
SCHEMBL31715425 0.76
SCHEMBL16969390 0.76 GAA (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223306-A1 TEAD INHIBITORS AND METHODS OF USE SPOROS BIOVENTURES, INC., 2025-07-10 US disclosed
CN-119522215-A TEAD inhibitors and methods of use 思博睿生物探索公司 2025-02-25 CN disclosed
EP-4496789-A1 TEAD INHIBITORS AND METHODS OF USE Sporos Biodiscovery, Inc. (US) 2025-01-29 EP disclosed
CN-119384498-A Methods and compositions for genetic modification of cells 因特利亚治疗公司 2025-01-28 CN disclosed
CN-117940426-A DNA-dependent protein kinase inhibitors, compositions and uses thereof 英特利亚治疗股份有限公司 2024-04-26 CN disclosed
CN-117835968-A Lipid nanoparticle compositions 英特利亚治疗股份有限公司 2024-04-05 CN disclosed
US-20240076294-A1 THERAPEUTIC COMPOUNDS AND METHODS ACTIO BIOSCIENCES, INC. 2024-03-07 US disclosed
CN-117479926-A Lipid nanoparticle compositions 英特利亚治疗股份有限公司 2024-01-30 CN disclosed
US-20240024478-A1 Compositions and Methods for Reducing HLA-A in a Cell INTELLIA THERAPEUTICS, INC. (US) 2024-01-25 US disclosed
US-20240024478-A1 Compositions and Methods for Reducing HLA-A in a Cell INTELLIA THERAPEUTICS, INC. (US) 2024-01-25 US disclosed
US-7723378-B2 G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease ACTELION PHARMACEUTICALS LTD. (CH) 2010-05-25 US disclosed
US-20080287415-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof SECOND GENOME, INC. 2008-11-20 US disclosed
US-20080287415-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof SECOND GENOME, INC. 2008-11-20 US disclosed
WO-2008112205-A1 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS, INC. (US) 2008-09-18 WO disclosed
US-20080176926-A1 G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease ACTELION PHARMACEUTICALS LTD. (CH) 2008-07-24 US disclosed
EP-1910364-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2008-04-16 EP disclosed
EP-1863787-A1 HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS Actelion Pharmaceuticals Ltd. (CH) 2007-12-12 EP disclosed
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2007-01-25 US disclosed
WO-2007011833-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2007-01-25 WO disclosed
WO-2006100631-A1 HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2006-09-28 WO disclosed